Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow ALT by emailGet an email when ALT pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ALT, unsubscribe in one click. Privacy
📣 What ALT Says Is Next
in 2026 · “In June 2026 , the Company announced plans to relocate its corporate headquarters to Morristown, New Jersey later in 2026 Financial Results for the Three Months Ended June 30, 2026”
Company press release, Aug 12, 2026 · SEC filing
in 2029 · “In August 2026, the Company announced the initiation of the global PERFORMA Phase 3 MASH trial, with 52-week data readout anticipated in 2029 o The PERFORMA trial is a Phase 3, Global, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects with MASH Alcohol Use Disorder (AUD)”
Company press release, Aug 12, 2026 · SEC filing
second half of 2026 · “The Company expects to initiate its global PERFORMA Phase 3 MASH trial in the second half of 2026, with 52-week data readout anticipated in 2029 o The PERFORMA trial is a Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects with MASH”
Company press release, May 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full ALT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.